HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7

Benzinga · 3d ago
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.